BioLife Solutions, Inc. BLFS R2K
Healthcare · Medical Instruments & Supplies · United States
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
READ MORE ›$24.92
+13.89% 1Y
Market & Price
Market Cap
$1.22B
Current Price
$24.92
High / Low (52W)
$28.79 / $18.15
Beta
1.97
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
85.93
PEG Ratio
15.09
Book Value
$7.62
Price to Book
3.27
P/S
11.98
EV/EBITDA
266.46
Dividend Yield
-
Profitability & Returns
ROCE
-4.34%
ROE
-3.09%
ROA
-0.09%
Profit Margin
-2.91%
Op Margin
0.10%
EPS (Latest Qtr)
$0.02
EPS (TTM)
$-0.24
Balance Sheet & Liquidity
Debt/Equity
3.99
Quick Ratio
5.15
Current Ratio
7.30
Debt
$14.86M
Total Assets
$405.88M
Current Assets
$136.56M
Working Capital
$113.58M
Ownership
Promoter Holding
2.39%
Chg in Prom Hold
-
FII / Inst Holding
104.35%
Chg in FII Hold
-0.00%
Financial Snapshot
Enterprise Value
$1.15B
Total Revenue (TTM)
$101.66M
EBITDA
$4.32M
Free Cash Flow
$6.39M
Operating Cash Flow
$17.90M
Shares Outstanding
48.86M
Gross Margin
63.76%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
8.07%
Profit 5Y
32.24%
Revenue (YoY)
24.70%
Earnings (YoY)
-
PROS
- Profit CAGR of 32.2% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BLFS BioLife Solutions, Inc. R2K | 24.92 | - | $1.22B | - | -4.34% | -3.09% | 8.07% | 32.24% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.17M | 2.07M | 1.21M | 1.24M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.05M | 25.42M | 28.07M | 18.79M | 27.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.25M | 8.99M | 10.15M | 6.81M | 10.00M |
| Gross Profit | 888.86K | 903.39K | 545.32K | 588.39K | 882.62K | 818.65K | 973.38K | 1.08M | 1.12M | 1.21M | 1.44M | 1.60M | 1.87M | 2.45M | 3.64M | 3.69M | 4.12M | 4.74M | 4.52M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.80M | 16.43M | 17.92M | 11.98M | 17.50M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.30M | 33.08M | 18.01M | 10.63M | 17.47M |
| Operating Income | -110.09K | -369.04K | -887.87K | -874.51K | -1.16M | -1.16M | -1.30M | -1.49M | -1.59M | -1.14M | -464.04K | -341.20K | -32.34K | 140.00K | 1.28M | 1.20M | 566.00K | 747.00K | -772.00K | 370.00K | 44.00K | -1.25M | -981.00K | -4.55M | -11.16M | -7.97M | -76.56M | -11.74M | -13.61M | -10.63M | -15.47M | -3.29M | -1.31M | - | - | -499.00K | -16.64M | -89.00K | 1.35M | 27.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 885.00K | -15.26M | 1.25M | 1.93M | 726.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 267.00K | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 285.00K | -15.71M | 703.00K | 3.36M | 1.25M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00K | 126.00K | 82.00K | -173.00K | 62.00K |
| Net Income | -309.91K | -559.37K | -883.36K | -862.46K | -1.03M | -994.38K | -1.07M | -1.23M | -1.36M | -969.00K | -870.29K | -768.21K | -318.72K | 4.87M | -26.35M | -24.46M | -19.16M | 4.25M | 10.27M | 22.31M | -16.38M | -1.13M | -1.12M | 7.88M | 79.00K | -7.42M | -72.88M | -10.32M | -13.71M | -10.20M | -29.13M | -10.22M | -20.72M | - | - | -448.00K | -15.84M | 621.00K | 11.07M | 1.19M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.06 | -0.03 | -0.02 | -1.74 | -1.42 | -1.03 | 0.02 | 0.35 | -0.01 | -0.70 | -0.04 | -0.03 | 0.19 | 0.00 | - | -1.72 | -0.24 | -0.32 | -0.23 | -0.67 | -0.22 | -0.45 | - | - | -0.01 | -0.33 | 0.01 | 0.22 | 0.02 |
| R&D Expense | 160.53K | 167.29K | 192.78K | 153.33K | 322.17K | 301.33K | 329.53K | 504.24K | 599.03K | 496.87K | 286.75K | 318.61K | 293.09K | 346.00K | 325.00K | 312.00K | 359.00K | 691.00K | 1.03M | 1.66M | 1.48M | 1.73M | 1.99M | 3.04M | 3.22M | 3.78M | 3.43M | 3.42M | 4.15M | 3.79M | 3.74M | 2.08M | 2.03M | 1.89M | - | 1.44M | 2.72M | 2.71M | - | 2.65M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.08M | 2.76M | 5.66M | 8.95M | 6.19M | - | - | - | - | - | - | - | 76.24M | 68.02M | 74.65M | 96.21M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 29.33M | 26.70M | 24.55M | 34.10M |
| Gross Profit | 856.39K | 1.40M | 2.29M | 3.76M | 3.04M | 3.81M | 4.78M | 6.75M | 13.53M | - | - | - | 46.91M | 41.32M | 50.10M | 62.12M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 57.59M | 60.72M | 54.57M | 78.72M |
| Operating Income | -1.39M | -1.21M | -942.24K | -285.36K | -3.14M | -5.02M | -4.85M | -1.06M | 3.66M | -220.00K | -6.24M | - | -10.68M | -19.40M | -4.48M | -16.60M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 5.79M | -7.10M | 4.18M | -11.91M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -4.85M | -12.22M | -8.82M | -12.08M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -5.24M | -64.00K | -38.00K | 49.00K |
| Net Income | -1.98M | -1.96M | -1.66M | -1.08M | -3.22M | -4.21M | -6.88M | -2.52M | -25.00M | -1.66M | 1.98M | - | -139.81M | -68.00M | -20.18M | -4.59M |
| Diluted EPS | - | - | - | - | - | - | - | -0.21 | -1.56 | -0.09 | -0.06 | - | -3.29 | -1.55 | -0.44 | -0.10 |
| R&D Expense | 318.90K | 516.45K | 463.64K | 487.82K | 871.10K | 1.38M | 2.03M | 1.19M | 1.30M | 3.17M | 6.72M | 11.82M | 8.67M | 5.51M | 4.75M | 7.57M |
Compounded Sales Growth
| 5 Years: | 8.07% |
| 1 Year: | 24.70% |
Compounded Profit Growth
| 5 Years: | 32.24% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +13.89% |
| 6 Months: | -7.67% |
| 3 Months: | +2.98% |
| 1 Month: | +24.66% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.31M | 1.66M | 3.17M | 3.35M | 16.07M | 12.37M | 7.93M | 12.14M | - | 12.29M | 21.79M | 46.45M | 45.47M | 48.07M | 51.30M | 83.79M | 92.82M | 234.83M | - | 450.23M | 412.71M | 399.49M | 405.88M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 138.45M | 120.60M | 148.76M | 136.56M |
| Cash & Equivalents | 139.15K | 3.21K | 16.86K | 196.48K | 156.27K | 2.54M | 2.17M | 1.41M | 6.66M | - | 7.03M | 14.17M | 32.38M | 30.66M | 31.82M | 19.62M | 21.20M | 6.45M | 90.40M | - | 19.44M | 27.90M | 91.54M | 33.04M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.90M | 27.16M | 29.01M | 30.16M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.94M | 7.90M | 8.48M | 7.95M |
| Total Liabilities | - | 10.86M | 12.84M | 15.66M | 16.62M | 2.14M | 2.51M | 4.76M | 2.05M | - | 16.55M | 34.73M | 52.94M | 30.84M | 51.81M | 49.23M | 48.60M | 49.36M | 29.58M | - | 86.04M | 75.05M | 50.58M | 34.00M |
| Current Liabilities | - | 340.70K | 579.25K | 1.37M | 1.63M | 1.26M | 1.73M | 1.13M | 1.51M | - | 1.31M | 1.66M | 2.10M | 1.94M | 2.70M | 3.16M | 5.01M | 7.67M | 15.57M | - | 44.58M | 42.18M | 32.73M | 22.98M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 655.00K | 6.35M | 23.79M | 17.56M | 5.00M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.71M | 33.83M | 30.04M | 17.90M |
| Total Equity | -7.83M | -9.55M | -11.18M | -12.49M | -13.27M | 13.94M | 8.51M | 3.17M | -9.53M | -9.53M | -4.25M | -12.94M | -6.50M | 14.63M | -3.74M | 2.07M | 35.19M | 43.32M | 204.43M | - | 364.19M | 337.66M | 348.91M | 371.89M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.83M | 45.17M | 46.91M | 48.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.25M | -989.92K | 854.93K | 146.01K | -3.16M | -4.97M | -4.33M | 605.00K | 2.35M | 1.21M | 6.64M | - | -8.49M | -12.50M | 8.43M | 20.11M |
| Investing Cash Flow | -28.41K | -91.43K | -1.15M | -236.67K | -8.14M | 4.24M | 392.79K | -144.00K | -6.50M | -27.02M | -24.71M | - | -58.12M | 17.84M | 58.30M | -71.54M |
| Financing Cash Flow | 1.15M | 1.09M | 475.00K | 50.46K | 13.68M | 368.75K | 3.17M | 4.80M | 28.15M | 1.60M | 102.08M | - | 16.32M | 10.59M | -6.78M | -10.92M |
| Capital Expenditure | -28.41K | -93.53K | -1.15M | -236.67K | -589.68K | -134.01K | -143.53K | -144.00K | -500.00K | -675.00K | -1.96M | - | -10.38M | -6.38M | -3.53M | -19.70M |
| Free Cash Flow | -1.28M | -1.08M | -296.79K | -90.66K | -3.75M | -5.11M | -4.47M | 461.00K | 1.85M | 538.00K | 4.68M | - | -18.87M | -18.88M | 4.90M | 416.00K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -50.29M | 15.93M | 59.95M | -62.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 41.1% | 50.9% | 40.5% | 42.0% | 49.0% | - | - | - | - | - | - | - | 61.5% | 60.7% | 67.1% | 64.6% |
| Operating Margin % | -67.0% | -43.8% | -16.6% | -3.2% | -50.7% | - | - | - | - | - | - | - | -14.0% | -28.5% | -6.0% | -17.3% |
| Net Margin % | -95.3% | -70.9% | -29.3% | -12.1% | -52.0% | - | - | - | - | - | - | - | -183.4% | -100.0% | -27.0% | -4.8% |
| ROE % | 20.8% | 17.5% | 13.3% | 8.2% | -23.1% | -49.5% | -217.1% | 26.4% | -170.9% | -3.8% | 1.0% | - | -38.4% | -20.1% | -5.8% | -1.2% |
| ROCE % | -144.0% | -111.7% | -52.2% | -16.5% | -21.2% | -47.1% | -71.4% | -9.9% | 8.4% | -0.3% | -2.8% | - | -2.6% | -5.2% | -1.2% | -4.3% |
Shareholding Pattern
Insiders
2.39%
Institutions
104.35%
Public Float
106.90%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 13.32% | 6.51M | $162.14M |
| 2 | Blackrock Inc. | 12.49% | 6.10M | $152.06M |
| 3 | Casdin Capital, LLC | 12.19% | 5.96M | $148.45M |
| 4 | Invesco Ltd. | 4.81% | 2.35M | $58.53M |
| 5 | Vanguard Capital Management LLC | 3.93% | 1.92M | $47.79M |
| 6 | State Street Corporation | 3.23% | 1.58M | $39.30M |
| 7 | FMR, LLC | 3.01% | 1.47M | $36.64M |
| 8 | Massachusetts Financial Services Co. | 2.45% | 1.20M | $29.84M |
| 9 | Fred Alger Management, LLC | 2.21% | 1.08M | $26.91M |
| 10 | Dimensional Fund Advisors LP | 2.12% | 1.04M | $25.81M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BLFS
No recent headlines available.